AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Biodexa Pharmaceuticals plc American Depositary Shs
XNAS · usd
SIC 8731 · SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
FIGI BBG00BLVW3G4
0.42▲ 0.01 (2.25%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
—
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
0.41
Day's Range
0.38 – 0.43
52-Week Range
0.34 – 8.94
Volume
229.9K
Avg Volume
4.5M
Share Statistics
Shares Outstanding
Employees
11
Exchange
XNAS
Listed
2015-12-07
Share count as of December 31, 2025

Biodexa Pharmaceuticals plc American Depositary Shs (BDRX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Biodexa Pharmaceuticals plc American Depositary Shs (BDRX)
What is Biodexa Pharmaceuticals plc American Depositary Shs's Market Cap?
Biodexa Pharmaceuticals plc American Depositary Shs's Market Cap is $95.6B, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Enterprise Value?
Biodexa Pharmaceuticals plc American Depositary Shs's Enterprise Value is $95.6B, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Revenue (TTM)?
Biodexa Pharmaceuticals plc American Depositary Shs's Revenue (TTM) is $0.00, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Net Income (TTM)?
Biodexa Pharmaceuticals plc American Depositary Shs's Net Income (TTM) is -$11.4M, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Diluted EPS (TTM)?
Biodexa Pharmaceuticals plc American Depositary Shs's Diluted EPS (TTM) is -0.00, based on as-reported figures from SEC (XBRL) filings.
What is Biodexa Pharmaceuticals plc American Depositary Shs's Net Debt?
Biodexa Pharmaceuticals plc American Depositary Shs's Net Debt is -$4.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BDRXAs-filed SEC (XBRL) data
No Quarterly data available for this company — showing Annual instead. This company files annual reports only — foreign private issuers (Form 20-F / 40-F) are not required to file quarterly reports, so no quarterly figures exist to show.
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of GBP, except per-share data)
Source: Akyla.ai
Line ItemDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017
Profit or loss [abstract]
Revenue—
Research and development costs
Administrative costs
Loss from operations
Interest Income
Finance expense
Loss before tax
Taxation
Items that will or may be reclassified subsequently to profit or loss:
Exchange (loss)/gains arising on translation of foreign operations—
Total comprehensive loss attributable to the owners of the parent
Loss per share
Earnings Per Share (Basic)
Earnings Per Share (Diluted)